# numis

# Investor presentation

Interim results 2023





# Half year 2023 highlights

- Revenue of £63.8m, representing a decline of 14% compared to H1 FY22
  - IB revenues -12%
  - Equities revenue -17%
- Whilst our ECM market share in the UK has increased relative to the comparative period, overall market levels of issuance reduced further over the same period
- First ECM transaction led by our new Dublin office completed. We continue to build our European client base, in line with the strategy to enhance our distribution capability beyond the UK
- Record half year advisory revenue performance reflects how our diversified business model continues to deliver a strong performance through the market cycle
- Resilient equities performance reflecting the continued strength of our research offering and stability of our institutional relationships
- 6 Interim dividend of 6.0p consistent with H1 FY22, with a further £4.4m spent on share repurchases
- Our balance sheet remains strong with both liquidity and capital positions providing the group with capacity to deliver shareholder returns and invest in our strategy to deliver growth through the market cycle
- The outlook for our advisory business remains positive with a good pipeline of both buy-side and sell-side mandates; some early indication of improvement in capital markets later in the year
- 9 Recommended all cash offer by Deutsche Bank for 350p per share announced April 2023




# Challenging markets for ECM and equities partially mitigated by M&A





# UK M&A<sup>(2)</sup> activity slowed in H1 (£bn)



- Macroeconomic headwinds have continued into the new financial year with inflation and rising interest rates leaving UK ECM volumes remaining at 10 year lows
- Investor sentiment toward the UK generally remained weak with domestic focused institutional investors experiencing persistent fund outflows. Despite the challenging backdrop, UK markets optically performed relatively well with the FTSE 100 and FTSE 250 up 11% and 10% respectively
- Whilst M&A volumes also declined across the period, activity levels have been generally more resilient compared to capital markets, particularly in the UK mid market where valuations of listed companies remain attractive notwithstanding some recovery in market levels.




(2) UK M&A activity refers to public markets only Source: Dealogic, Bloomberg and Thomson Reuters Eikon

<sup>(1)</sup> Market size: H1 2023 vs. H1 2022 (2) UK M&A activity refers to public markets only

# Continued advisory growth partially offset broader revenue decline

#### HI performance reflects continued weakness in capital markets



### Income analysis


£m	H1 FY23	H1 FY22	H2 FY22	Change vs. H1 FY22	Change vs. H2 FY22
Capital markets	11.9	24.7	18.0	(51.9%)	(34.3%)
Advisory	24.2	17.2	21.8	40.3%	11.1%
Retainers	6.1	6.1	6.3	0.1%	(2.7%)
IB Revenue	42.2	48.0	46.1	(12.2%)	(8.5%)
Institutional income	17.4	19.6	17.7	(11.1%)	(1.3%)
Trading	4.2	6.5	6.3	(35.8%)	(33.8%)
Equities Revenue	21.6	26.1	24.0	(17.3%)	(9.9%)
Investment income	0.5	0.4	(1.9)	22.8%	(129.0%)
Total income	64.3	74.6	68.2	(13.8%)	(5.7%)
Deal Fee Revenue	36.1	41.9	39.8	(14.0%)	(9.4%)

- Record advisory revenue performance, up 40% on HI FY22
- Capital markets revenue decline in a continued period of industry wide drop in deal volumes
- First ECM transaction led by our new Dublin office completed, pick up in private markets deal activity seen
- Challenges still remain in equity markets, as investor sentiment continues to be impacted by the uncertain macro-economic outlook, some early indication of improvement in capital markets later in the year
- Against a market backdrop of falling equity markets and persistent outflows from UK funds both institutional income and trading businesses experienced a weaker end to the half year.




# Corporate broking client base progression


### Revenue from client base and client profitability remains high



#### IB client base growth impacted by higher M&A activity



## Corporate broking client activity \*



- Corporate clients have reduced slightly to 166, primarily due to the high number of takeovers in the period. Of the nine clients lost to transactions, eight were supported by Numis
- Average market cap of our corporate client base has remained over £1.0bn and average tenure of more than seven years
- Second best half year performance for % of deal revenue from our corporate client base, and third best for deal fee revenue per client, reflecting our long term focus on high quality and active clients
- Total average deal fees have increased 32% relative to H1 FY22, with increases seen in both M&A and capital markets reflecting sustained investment in our IB capabilities despite lower market volumes.



<sup>\* %</sup> of existing clients as at the beginning of the year who have completed a transaction (annualised)

# Record M&A half year performance

One of the most active and expert financial advisers in the UK public mid-market

Since January 2022:

18+

M&A transactions advised on

>£26bn

total transaction value

Significant market share of UK midmarket public defence deals \*

numis

## Broad focus to provide finessed advice both UK and internationally

- · Long-term focus on expanding M&A capabilities in investment banking
- Enhanced strategic engagement with clients from greater sector alignment. 98% of M&A fees in H1 FY23 were originated from the retained client list
- Improvement in M&A execution capability
- Significantly increased engagement with private equity
- Strong credentials over last two years supports further financial adviser appointments
- M&A revenues were higher than UK ECM revenue for the first time demonstrating our progress in diversifying the business
- Average H1 FY23 M&A fees increased 204% vs. H1 FY22



c.£306m possible offer by Providence Equity

Joint financial adviser and sole corporate broker

Ongoing



Recommended c.£271m cash offer by Sun European Partners

Sole financial adviser and corporate broker and nomad

Feb 2023

Recommended c £3.9bn cash offer for c.41% by Schneider Electric

Joint financial adviser and joint corporate broker

Jan 2023



#### COUNTRYSIDE

Recommended c.£1.3bn cash and share combination with Vistry

Joint financial adviser and joint corporate broker

Nov 2022

### Bluestar Group

Possible offer to acquire Home REIT

Sole financial adviser

Ongoing



Recommended c.fl.8bn cash offer by Open Text

Joint financial adviser and joint corporate broker

Jan 2023

## FRASERS GROUP

c.£13.6m offer to acquire MySale Group

Sole financial adviser

Dec 2022

# **M&C SAATCHI GROUP**

Successful defence from hostile offer by AdvancedAdvT

Joint financial adviser and joint corporate broker

Sep 2022

#### **EMIS**Group

Recommended c.£1.2bn cash offer by UnitedHealth Group

Sole financial adviser, sole corporate broker and nomad

Announced



Recommended c.£1.3bn cash offer by Energy Capital Partners

Joint financial adviser and joint corporate broker

Jan 2023

Successful defence of possible offer by National World

Sole ffinancial adviser and joint corporate broker

Nov 2022




Recommended c.£870m cash offer by Sheikh Holdings

Joint financial adviser and joint corporate broker

Sept 2022

# Resilient equities performance given market conditions

# Equities revenue down with investor sentiment towards the UK remaining relatively weak (£m)




# % of gain days consistent with prior years despite market volatility





- Institutional income performance in line with H2 FY22, 11% decline on the same period last year, with domestic focused institutional investors experiencing persistent fund outflows during the period
- Research fees remained broadly flat
- Trading gains of £4.2m reflect a particularly weak Q2 performance
- The opening of our new Dublin office to enhance our distribution capability beyond the UK has seen us continue to build our European client base during the period
- Our Electronic Trading business closed post period end reflecting our assessment that this product was not core to our long term strategy.



# Investment in the platform and cost discipline through the cycle







- Total operating costs decreased by 3% to £58.2m
- Staff costs decreased by 7% due to lower variable compensation but comp ratio remains within our through the cycle target range
- During the first half we made a small number of headcount reductions in certain areas of the business whilst maintaining our focus on investing in strategic growth areas
- Non-staff costs increased 3% compared to the prior year. We incurred an additional £0.4m relative to the comparative period in relation to our new Dublin office, in addition to higher technology and market data costs.



# Investment portfolio

# Portfolio bridge £5.6m £0.8m £0.0m £17.7m £17.6m £0.7m (£6.9m)H1 FY22 Additions FX H1 FY23 Disposals FV increase FV reduction £3.9m £18.4m £0.0m £0.0m (£3.4m)


### Portfolio progression

£17.7m

H1 FY23

(£1.3m)

FX



- Our investment portfolio faced valuation headwinds as the higher interest rate environment led to continued pressure on the ratings of listed growth businesses, in addition to the weakening of the US Dollar over the period adversely impacting valuations
- The majority of the holdings incurred write downs during the half, however, the aggregate write down was more than offset by the upward re-valuation of Wiz following completion of their funding round in February 2023. This transaction was led by the Growth Capital Solutions team and demonstrates the strategic benefit of aligning our investment portfolio with our private markets activities
- The portfolio currently represents 10% of Group net assets.



H2 FY22

Additions

Disposals

FV increase


FV reduction

# Strong capital and liquidity position supports shareholder returns


### Issued share count broadly in line for the period



# Dividend (1) & buyback spend (excl. EBT) (£m)



## Cash position remains robust (£m)





- Interim dividend maintained at 6.0p in line with dividend policy
- Issued share count remains broadly in line with the comparative period end pursuant to our strategy to offset the dilutive impact of share awards though buybacks
- Shares repurchase spend of £4.4m, broadly in line with H2 FY22.
  Buyback programme suspended due to recommended acquisition
- Net assets of £179.6m down 6% relative to the prior year period.
  Strong surplus capital position post adoption of IFPR transition rules
- Cash position of £99.7m down 11% attributable to variable compensation payments related to the prior year, which were partially offset by short-term cash movements associated with trading and settlement activities.



(1) Dividend shown on a declared basis (2) One-off 5 year LTIP vesting

# Long track record of delivering growth, diversification and consistent returns across market cycles





#### 10 year shareholder returns (£m) £ 000 FY20 Dividends 8.206 12,582 On-market buyback 2.370 9.829 3,473 3.719 19,588 10,675 7.774 5.426 1.555 8.183 2.618 **Total returns** 23,438 20,424 18,008 14,281 23,763 10,825 12,140 21,429 16,361 17,250 33,061 PAT 18.064 31,350 13,700 4.898 Dividend payout 58% 136% 22% 114% 168% Total Payout (ex EBT) 221%





(1) Revenue excluding investment income / losses (2) FTSE250 price index at 30 Sep. Source: Bloomberg

# Deutsche Bank recommended cash acquisition of Numis Corporation PLC

- Announced all cash recommended offer on Friday 28 April 2023
- Cash consideration of 350p per share
  - 339p headline cash consideration
  - 6p pre-announced interim dividend
  - 5p second interim dividend conditional on the transaction closing
- Strategic rationale beneficial for all stakeholders
- Further details to come



# Key financials

£m	H1 2023	H1 2022	Change (%)
Revenue <sup>(1)</sup>	63.8	74.2	(14.0%)
Investment Income	0.5	0.4	22.8%
Staff costs <sup>(2)</sup>	36.5	39.0	(6.5%)
Non-staff costs	21.7	21.1	2.9%
Operating profit	6.1	14.4	(57.6%)
Underlying Operating profit	5.6	14.0	(60.1%)
PBT	6.0	13.4	(55.2%)
Net income	4.9	16.8	(70.8%)
EPS (pence) <sup>(3)</sup>	4.3p	14.6p	(70.6%)
Dividend (pence)	6.0p	6.0p	0.0%
Net Assets	179.6	190.8	(5.9%)
Cash and cash equivalents	99.7	111.5	(10.6%)
Underlying Operating profit margin	8.8%	18.9%	(10.1pp)



<sup>(1)</sup> Excluding gain/losses on investment portfolio (2) Including share scheme charges and variable compensation provision (3) Diluted

# numis

#### Offices

London	New York	Dublin
45 Gresham Street	575 Fifth Avenue	Riverview House
London	25 <sup>th</sup> Floor	21 – 23 City Quay
EC2V 7BF	New York, NY 10017	Dublin, D02 FP21
+44 (0)20 7260 1000	+1 212 277 7300	+353 1 574 7200

#### Important notice

#### Forward-looking statements

This presentation contains forward-looking statements. Forward-looking statements sometimes use words such as 'may', 'will', 'could', 'seek', 'continue', 'aim', 'anticipate', 'target', 'project', 'expect', 'estimate', 'intend', 'plan', 'goal', 'believe', 'achieve' or other words of similar meaning. Past performance is no guide to future performance and any forward-looking statements and forecasts are based on current expectations and assumptions but relate to events and depend upon circumstances in the future and you should not place reliance on them. These statements and forecasts are subject to various risks and uncertainties and there are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by forward-looking statements and forecasts.

The forward-looking statements contained in this document speak only as of the date of this presentation and (except as required by applicable regulations or by law) Numis does not undertake to publicly update or review any forward-looking statements, whether as a result of new information, future events or otherwise.

Nothing in this presentation constitutes or should be construed as constituting a profit forecast.

#### No offer of securities

The information, statements and opinions contained in this presentation do not constitute or form part of, and should not be construed as, any public offer under any applicable legislation, or an offer, or solicitation of an offer, to buy or sell any securities or financial instruments in any jurisdiction, or any advice or recommendation with respect to any securities or financial instruments.